Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
Authors
Keywords
-
Journal
PHARMACOECONOMICS
Volume 37, Issue 9, Pages 1177-1193
Publisher
Springer Science and Business Media LLC
Online
2019-06-20
DOI
10.1007/s40273-019-00812-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
- (2018) Max S. Topp et al. BLOOD
- Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal
- (2017) David M. Phillippo et al. MEDICAL DECISION MAKING
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute lymphoblastic leukemia: a comprehensive review and 2017 update
- (2017) T Terwilliger et al. Blood Cancer Journal
- Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
- (2017) Thomas E. Delea et al. JOURNAL OF MEDICAL ECONOMICS
- Burden of hospitalization in relapsed acute lymphoblastic leukemia
- (2016) A. Barlev et al. CURRENT MEDICAL RESEARCH AND OPINION
- International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
- (2016) N. Gokbuget et al. HAEMATOLOGICA
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
- (2016) N. Gokbuget et al. HAEMATOLOGICA
- How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
- (2015) N. V. Frey et al. BLOOD
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
- (2012) James E. Signorovitch et al. VALUE IN HEALTH
- Health Care Costs for Patients With Cancer at the End of Life
- (2012) Benjamin Chastek et al. Journal of Oncology Practice
- Deriving a Preference-Based Measure for Cancer Using the EORTC QLQ-C30
- (2011) Donna Rowen et al. VALUE IN HEALTH
- Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation
- (2010) Paul J. Martin et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation